Dr. Danny Y. Lin, MD

Dr. Lin practices at Eye Surgery Center of San Francisco in San Francisco, California.

Dr. Lin's NPI, 1871595710, was assigned on August 11, 2005. Dr. Lin graduated from Stanford University School Of Medicine in 1999. Dr. Lin's California license number on file is A72782.

Dr. Lin's primary practice is Eye Surgery Center of San Francisco, at 1160 Post Street, San Francisco, CA 94109. The practice phone is (415) 440-1100.

Dr. Lin's primary practice is Eye Surgery Center of San Francisco in San Francisco, California. Dr. Lin is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is North East Medical Services (NEMS). Dmand AI also links Dr. Lin to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lin is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Lin has a license on file in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and glaucoma surgery among the conditions Dr. Lin treats.

CMS data shows 2,201 Medicare services from Dr. Lin across 16 procedure codes in 2024, for 781 Medicare patients. Medicare paid $367,574 for them.

CMS counts 781 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 365 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 75, with 57% women.

In 2024, Dr. Lin wrote 1,712 Medicare Part D claims for 692 patients. 42% of them were for generic drugs. CMS names the drug for 1,648 of them, across 8 drugs with 11 or more claims each, at $74,951 in total drug cost. In 2023, CMS named 2,069 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 522 procedures of cataract surgery by Dr. Lin, more than 95% of the clinicians it reports for that procedure.

Dmand AI links 7 papers to Dr. Lin. The most frequent topics are Diabetic Retinopathy, Ophthalmoscopy and Postoperative Complications. Dr. Lin has published most often in J Cataract Refract Surg. Dr. Lin's most frequent co-authors are Mark Blumenkranz, MD, Edward Emanuel Manche, MD and Kuldev Singh, MD.

CMS Open Payments shows 184 general payments to Dr. Lin from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. RxSight Inc paid the most, $12,024.

Dmand AI lists 1 award for Dr. Lin.

Dr. Lin graduated from Stanford University School Of Medicine in 1999. Dr. Lin is a member of AAO.

Dr. Lin is in network with 15 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.